$8.35
0.71% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

ITeos Therapeutics Inc Stock price

$8.35
+1.73 26.13% 1M
+0.50 6.37% 6M
+0.67 8.72% YTD
-9.74 53.84% 1Y
-10.24 55.08% 3Y
-10.70 56.17% 5Y
-10.70 56.17% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.06 0.71%
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

Key metrics

Market capitalization $319.59m
Enterprise Value $-195.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.95
EV/Sales (TTM) EV/Sales -5.59
P/S ratio (TTM) P/S ratio 9.13
P/B ratio (TTM) P/B ratio 0.57
Revenue (TTM) Revenue $35.00m
EBIT (operating result TTM) EBIT $-152.32m
Free Cash Flow (TTM) Free Cash Flow $-100.33m
Cash position $520.37m
EPS (TTM) EPS $-3.23
P/E forward negative
Short interest 8.51%
Show more

Is ITeos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

ITeos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ITeos Therapeutics Inc forecast:

3x Buy
50%
3x Hold
50%

Analyst Opinions

6 Analysts have issued a ITeos Therapeutics Inc forecast:

Buy
50%
Hold
50%

Financial data from ITeos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
35 35
-
100%
- Direct Costs 1.26 1.26
31% 31%
4%
34 34
3,615% 3,615%
96%
- Selling and Administrative Expenses 46 46
8% 8%
132%
- Research and Development Expense 139 139
14% 14%
396%
-151 -151
12% 12%
-432%
- Depreciation and Amortization 1.26 1.26
31% 31%
4%
EBIT (Operating Income) EBIT -152 -152
12% 12%
-435%
Net Profit -131 -131
3% 3%
-374%

In millions USD.

Don't miss a Thing! We will send you all news about ITeos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ITeos Therapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival
Neutral
GlobeNewsWire
22 days ago
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics...
Neutral
GlobeNewsWire
about 2 months ago
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a...
More ITeos Therapeutics Inc News

Company Profile

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.

Head office United States
CEO Michel Detheux
Employees 173
Founded 2012
Website www.iteostherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today